http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#Head
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#assertion
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#provenance
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#pubinfo
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#assertion
http://purl.obolibrary.org/obo/DOID_2571
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2571
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00570
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
http://www.w3.org/2000/01/rdf-schema#label
vinblastine sulfate injection is indicated in the palliative treatment of the following i frequently responsive malignancies generalized hodgkin s disease stages iii and iv ann arbor modification of rye staging system lymphocytic lymphoma nodular and diffuse poorly and well differentiated histiocytic lymphoma mycosis fungoides advanced stages advanced carcinoma of the testis kaposi s sarcoma letterer siwe disease histiocytosis x ii less frequently responsive malignancies choriocarcinoma resistant to other chemotherapeutic agents carcinoma of the breast unresponsive to appropriate endocrine surgery and hormonal therapy current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents for enhanced therapeutic effect without additive toxicity agents with different dose limiting clinical toxicities and different mechanisms of action are generally selected therefore although vinblastine sulfate is effective as a single agent in the aforementioned indications it is usually administered in combination with other antineoplastic drugs such combination therapy produces a greater percentage of response than does a single agent regimen these principles have been applied for example in the chemotherapy of hodgkin s disease vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of hodgkin s disease advanced hodgkin s disease has also been successfully treated with several multiple drug regimens that included vinblastine sulfate patients who had relapses after treatment with the mopp program mechlorethamine hydrochloride nitrogen mustard vincristine sulfate prednisone and procarbazine have likewise responded to combination drug therapy that included vinblastine sulfate a protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced hodgkin s disease advanced testicular germinal cell cancers embryonal carcinoma teratocarcinoma and choriocarcinoma are sensitive to vinblastine sulfate alone but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents the effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin this schedule permits more cells to be arrested during metaphase the stage of the cell cycle in which bleomycin is active
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00570
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#provenance
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#pubinfo
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#sig
http://purl.org/nanopub/x/hasSignature
cfrOaF+MbGg0pcPyDoJZCtKJCbxmXznktP+P4MfSMVYEHuYKiptdOBJCsKuamBBK6NLD3xMH0xMguD/JgBfrGyzItCFvafguijBPGNG5da6lTnzDoRjEHEHamzeM9z9+fDadxewa3XuGiMl9Q7Vng+vHA4QqjO0fwQ5RAHn9Zds=
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
http://purl.org/dc/terms/created
2021-06-18T09:09:38.348+02:00
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAH8faNXZXxO5jUOjI5B6IrHmYkmj1N0_nBtS8OJFRGgE
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs